ES
Esperion Therapeutics, Inc.
ESPR · NASDAQ
$3.18 -0.16% (-$0.01)
Market Cap $661.1M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$3.97
24.8% upside
Current Price
$3.18
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ESPR is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
25 /100
Expensive EV/EBITDA 27.03x
P/S 1.58x
P/E N/A
Growth
100 /100
Growing Rev. growth 74.80%
EPS growth N/A
FCF growth N/A
Profitability
34 /100
Moderate Gross margin 31.38%
Net margin 1.77%
Op. margin 18.12%
Quality
73 /100
Excellent ROIC 41.20%
ROA 1.60%
Asset turnover 0.90x
Debt
16 /100
High Current ratio 1.53x
Int. coverage -451.60x
Net debt/EBITDA 9.99x
Stability
49 /100
Moderate Beta 1.06x
Rev. volatility 86.97%
EPS volatility 17.33%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ESPR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Sheldon L. Koenig
Employees
294
Headquarters
Ann Arbor